Lv1
20 积分 2025-08-08 加入
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
1小时前
待确认
Comprehensive population pharmacokinetic modelling of sugemalimab, an anti‐programmed death‐ligand 1 (PD‐L1) human monoclonal antibody, in patients with solid tumours or lymphomas across multiple Phase I–III studies
10天前
已完结
皖公网安备34019202002308
